NovoCure Ltd (NVCR) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
NovoCure Ltd
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Surgical & Medical Instruments & Apparatus
High 16.82 at 9:00 am ET, low 16.58 at 3:00 pm ET.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields (TTFields) devices for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and malignant pleural mesothelioma. The company markets its products in the European Union, the United Kingdom, Japan, and internationally. It has a clinical study collaboration agreement with MSD to study TTFields together with KEYNOTE, an anti-PD-1 therapy; and a strategic collaboration with Zai Lab (Shanghai) Co., Ltd. to commercialize its products in Greater China and establishes a development partnership intended to accelerate the development of TTFields in multiple solid tumor cancer indications. NovoCure Limited was incorporated in 2000 and is based in Saint Helier, Jersey.
the bull case· 3
215
managers reporting a position in regulatory institutional filings
13fJun 30 '2624
managers whose positions together make up the majority of reported value
13fJun 30 '263
disclosed supplier and customer ties in corporate filings
sec filingsedgarthe bear case· 4
0.05%
of an index fund's assets the largest fund weight on file
n-portJun 30 '266 of 23
of the largest reporting managers reduced their stake in the most recent quarter
13fJun 30 '26−0.02%
change in shares held by the largest reporting managers over the latest quarter
13fJun 30 '265 of 8
recent reports where the move came in under the options implied range
earnings historyimplied vs realizedSides and captions by the model; every figure is ours. Built Sep 16 '26 for the Oct 29 '26 report. Not a forecast, not advice.
Of the 6 companies NovoCure Ltd moves with most closely, none share its SEC classification.
Measured against 499 trading days of our own closes. Co-movement, not cause.
SIC 3841, Surgical & Medical Instruments & Apparatus, from each company's own filings. Largest first.
216 managers report a position worth $1.6B between them, and 24 of them hold 80% of it.
tall tick = annual report · 1 on record
NVCR (NovoCure Ltd) has 0 disclosed suppliers and 3 disclosed customers, strongest disclosure first.
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.